Takeda and Lilly hit by $9bn Actos damages
This article was originally published in Scrip
Shares in Japanese major Takeda Pharmaceutical fell by more than 8% (JPY4,396) after a US jury ordered it to pay $6bn in punitive damages after finding it concealed the risk of cancer associated with the antidiabetic Actos (pioglitazone). Co-defendant Eli Lilly was also ordered to pay $3bn.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.